Amylyx Pharmaceuticals (AMLX) EBT (2021 - 2026)

Amylyx Pharmaceuticals' EBT history runs 6 years deep, the most recent figure standing at -$91.0 million for Q1 2026.

• On a quarterly basis, EBT fell 153.29% year-over-year to -$91.0 million in Q1 2026; TTM through Mar 2026 was -$199.7 million, a 9.0% increase from a year earlier, with the FY2025 full-year figure at -$144.7 million, up 52.11% from the prior year.
• EBT slipped to -$91.0 million in Q1 2026 per AMLX's latest filing, from -$33.0 million in the prior quarter.
• Across five years, EBT topped out at $24.0 million in Q2 2023 and bottomed at -$118.6 million in Q1 2024.
• The 5-year median for EBT is -$41.4 million (2025), against an average of -$40.2 million.
• Across the five-year window, EBT soared 144.55% in 2023 and slumped 8549.82% in 2024, its largest moves.
• Year by year, EBT stood at -$43.2 million in 2022, then surged by 110.28% to $4.4 million in 2023, then slumped by 959.55% to -$38.2 million in 2024, then advanced by 13.69% to -$33.0 million in 2025, then plunged by 176.0% to -$91.0 million in 2026.
• Per Business Quant, the three latest AMLX EBT figures stand at -$91.0 million (Q1 2026), -$33.0 million (Q4 2025), and -$34.4 million (Q3 2025).